Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis (StopRA)

Objective

This is a phase 2 multicenter, randomized, placebo-controlled, double-blind, parallel-group, 36-month clinical trial to evaluate the effectiveness and safety of intervention with a 12-month course of Hydroxychloroquine to prevent the future onset of clinically-apparent Rheumatoid Arthritis.

Location:

Essentia Health Duluth

Disclosures:

None

For more information about a financial conflict of interest (FCOI), review the Essentia Health FCOI policy.

Last Updated: 05/12/2016

Research Study Categories

  • Adult Studies

Specialty

  • Rheumatology
Contact
Clinical Trials at 866-839-4128
or clinicaltrials@eirh.org